// App-Quantinova.ai

21 : Long Term Survival of GOG 252 ‘Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/GOG Study’

Researchers

Presenter

  • Joan Walker

Principal Investigators

  • Brady Mark

  • Kathleen Moore

  • Krishnansu Tewari

  • Premal Thaker

  • Paul DiSilvestro

  • Linda Van Le

  • Saketh Guntupalli

  • Heidi Gray

  • Peter Rose

  • David Alberts

  • Keiichi Fujiwara

  • Robert Mannel

  • Carol Aghajanian

  • Larry Copeland

  • Gini Fleming

Medical Centers

  • The Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain

  • Institut Català d’Oncologia Badalona Hospital Universitari Germans Trias i Pujol, Badalona, Spain

  • European Institute of Oncology, Milan, Italy

  • Istituto Nazionale Tumori di Napoli Fondazione G Pascale IRCCS, Napoli, Italy

  • US Oncology Research, Texas Oncology, The Woodlands, TX, United States

  • Ghent University Hospital, Ghent, Belgium

  • Fondazione Policlinico Universitario A. Gemelli, IRCCS and Catholic University, Rome, Italy

  • Memorial Sloan Kettering Cancer Center, New York, NY, United States

  • Bon Secours Hospital, Cork, Ireland

  • ImmunoGen, Waltham, MA, United States

  • Kliniken Essen-Mitte Knappschafts-Krankenhaus, Essen, Germany

  • University of Leuven, Leuven, BELGIUM

  • Dana-Farber Cancer Institute, Boston, MA, United States

Locations

  • United States

  • Brazil

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Oncology (ONC)

Disease

  • Ovarian cancer

Biomarkers

  • Cancer antigen 125

Drug/Treatment

  • Bevacizumab

  • Carboplatin

  • Paclitaxel

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved